AzTrials
AzTrials

UrolithiasisNCT06211842

Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study

An observational study of Urolithiasis, run by University Hospital Southampton NHS Foundation Trust.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Many things, like not drinking enough fluids, contribute to making kidney stones and there is also a genetic tendency. We looked into this in 1998-2000 in 14 families with several stone-formers. In four of these the risk for stones was passed down through one line of the family. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Urolithiasis
How many people
47 participants
Where
No sites listed yet
Study dates
12 Oct 2016to 8 Nov 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Four families met the above criteria. A total of 77 family members in primary care were eligible. Of these: 71 were contacted: 47 were recruited; 3 declined; and 21 did not respond to two letters of invitation

Who may be able to join

  • Stone-forming families who participated in our 1998-2000 study
  • Apparent autosomal dominant inheritance of stones transmitted through one line of the family.
  • Calcium kidney stone formers.
  • Men and women aged 18 year or over.

Who cannot join

  • A known hereditary cause of stones
  • Children under 18 years of age.
  • Uric acid stone formers.

About this study

Many things, like not drinking enough fluids, contribute to making kidney stones and there is also a genetic tendency. We looked into this in 1998-2000 in 14 families with several stone-formers. In four of these the risk for stones was passed down through one line of the family. We have now had a close look at the DNA of 47 members of these four families using a very sensitive technique called exome sequencing. We wanted to see if these individuals had inherited any rare changes (variations) in their DNA which would add to their risk of making stones. We found 11 variations which might be important. Surprisingly, these were not in genes which have been regarded as the main causes of stones. Most of them are unfamiliar to clinicians and scientists world-wide. Experts on the genes gave us helpful advice about the likely significance of the variations. Researchers in Paris, Lille and the UK (Oxford, Cambridge and Sheffield) did analyses to help to decide this. An exciting finding was that one of the variants, not previously identified in stone formers, had just been found in a large Italian family with stones. This small study has shown that: variations in a wide range of genes may contribute to stone formation; these occur in genes that we have not come across before; further laboratory studies are essential to investigate potentially important variants; sharing findings between laboratories doing similar studies world-wide is crucial.

Read the detailed description

Background:

There is an underlying genetic component to formation of calcium kidney stones, with heritability estimated at about 50%. In most stone formers, genetic susceptibility is polygenic with co-inheritance of multiple small effect gene variants. Genome wide association studies have identified common polymorphisms in 31 genes associated with stone formation. Like other complex polygenic disorders, these do not fully account for genetic susceptibility. Rare/low-frequency variants are also likely to contribute.

In this small observational study, DNA was analysed from members of four calcium stone-forming families in which the risk for stones showed apparent autosomal dominant inheritance. The findings were related to biochemical data obtained in earlier investigations.

Primary objective: to identify rare gene variants associated with stone formation.

Secondary aim: to look for association of the variants with biochemical risk factors for stones recorded in 1998-2000.

Study participants In 1998 to 2000, fourteen families with at least three first-degree relatives who produced calcium stones participated in a study to look for segregation of five genes associated with stone formation. They had biochemical investigations and DNA was analysed using microsatellites. The results were negative. In four of the families, stones had apparent autosomal domain inheritance. Forty- seven of their members were recruited to the new study.

Methods DNA extracted from stored frozen blood was analysed by whole exome sequencing (WES) from ten stone formers (three from each of three families and one from the fourth), and from three members from one kindred who had low excretion of urinary citrate, a stone risk factor. Sequence data were first cross-referenced against a panel of 367 candidate genes reported to be associated with stones, intermediate traits and renal function. Since nephrolithiasis is a relatively common condition, a minor allele frequency of less than or equal to 2% (MAF≤0.02) was applied to retain rare and low frequency variants. We then analysed all other variants from across the genome that were present in all three stone formers within each family that underwent WES. We applied aggressive filtering to this very large dataset. The relevance of each variant to stones was reviewed using the DISEASE database and extensive literature review, and those considered to be significant were prioritised. To examine the association of variants selected for each kindred with stones, they were tracked across the pedigree by Kaspar analysis of DNA from all family participants. [1] Results summary

1 Collectively 20 rare variants (polymorphisms) predicted in silico to be pathogenic and potentially relevant to urolithiasis were identified in the stone formers. Tracking studies for 9 variants showed poor segregation with stones arguing against (but not excluding) a role in stone formation.

  1. The clutch of variants was different for each family. 3. Surprisingly, the variants were not in genes which have been regarded as the main causes of stones. Most of them are unfamiliar to clinicians and scientists world-wide.
  2. To assess the likely significance of our prioritised variants, we obtained advice from the few groups world-wide with a research interest in the relevant genes. Researchers in Paris, Lille and the UK (Oxford, Cambridge and Sheffield) did preliminary functional analyses to help. However, none had the capacity to do more.
  3. From the exome sequences one variant was reported as a pathogenic variant of TCAF2*, the gene for a protein that inactivates a plasma membrane calcium channel. This variant was ultimately demonstrated to be in an inactive pseudogene and not significant.

6 At the time of our study one variant, in the mitochondrial Mg-ATP transporter SLC25A25*, not previously identified in stone formers, was found in a large Italian family with stones. [1] 7. Stone formers with the SLC25A25 and MEPE* variants had phosphaturia. 8. No rare variants associated with low citrate excretion in the family investigated.

Conclusions i) Variations in a wide range of genes may contribute to stone formation; these occur in genes that we have not come across before. ii) Further laboratory studies are essential to investigate potentially important variants, but this is seldom achievable because of limited capacity world-wide to investigate the genes involved. iii) Results reported from exome screens are fallible - pseudogenes are one source of error. iv) Sharing findings between laboratories doing similar studies world-wide is crucial.

  • TCAF2 TRPM8 Channel-Associated Factor 2; SLC25A25 Solute Carrier Family 25 Member 25; MEPE matrix extracellular phosphoglycoprotein.

[1] Jabalameli MR, Fitzpatrick FM , Colombo R et al. Exome sequencing identifies a disease variant of the mitochondrial ATP-Mg/Pi carrier SLC25A25 in two families with kidney stones Mol Genet Genomic Med. 2021 Dec;9(12):e1749. doi: 10.1002/mgg3.1749.

Conditions
Urolithiasis
Keywords
gene polymorphisms
Medical subject headings
Urolithiasis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gene variants linked to kidney stone formation

    The number of stone-formers within a kindred with a gene variant relevant to stones compared with the number of non-stone formers with the variant in the kindred. Stone formation ascertained from interviews with family members in 1998-2000, follow-up questionnaires in 2016 and hospital records.

    Measured: up to 12 months from end of the study to complete functional studies of identified variants

Secondary outcomes (1)
  1. Gene variants linked to biochemical traits which increase the risk for kidney stones.

    All participants were tested in 1998-2000 for fifteen well recognised biochemical abnormalities which increase stone risk. For each risk factor, pedigree members are now categorised as to whether they had the biochemical abnormality or not. For those with the abnormality, the number with an abnormal gene variant are compared with the number without. Similarly for those with normal biochemical values, the number with a gene variant and the number without are compared.

    Measured: up to 12 months from end of the study to complete functional studies of identified variants

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jan 2024
  2. Study start12 Oct 2016
  3. Primary completion25 May 2022
  4. Study completion8 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Family based
Time perspective
Retrospective
Enrolment
47 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06211842
Sponsor's protocol ID
RHM PAT0295
Status last verified
Jan 2024
First submitted
22 Dec 2023
Last updated
19 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Anonymised patient data will be shared with a responsible investigator through a personal request to Dr Valerie Walker or the PI

Publications

  • Jabalameli MR, Fitzpatrick FM, Colombo R, Howles SA, Leggatt G, Walker V, Wiberg A, Kunji ERS, Ennis S. Exome sequencing identifies a disease variant of the mitochondrial ATP-Mg/Pi carrier SLC25A25 in two families with kidney stones. Mol Genet Genomic Med. 2021 Dec;9(12):e1749. doi: 10.1002/mgg3.1749. Epub 2021 Aug 4.

    PubMed 34346195

Questions about this trial

What is this clinical trial studying?

An observational study of Urolithiasis, run by University Hospital Southampton NHS Foundation Trust.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gene variants linked to kidney stone formation (time frame: up to 12 months from end of the study to complete functional studies of identified variants). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06211842, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in